ALX Oncology Holdings Inc. ALXO
1.14 USD -0.23 (-16.54%)
Nov 5, 2026, 3:59 PM EST
1.13 Day range 1.37
0.862 52-week range 2.66
- YTD
- +0.44%
- 1 year
- -9.92%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics…
benzinga.com ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression…
globenewswire.com ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression…
defenseworld.net 7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc. BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
globenewswire.com ALX Oncology to Present at Upcoming Investor Conferences in September SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel…
defenseworld.net 5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO 5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the…
zacks.com Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
benzinga.com ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 75 percent increase over losses of…
globenewswire.com ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive…
globenewswire.com ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel…- benzinga.com ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today…
globenewswire.com ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph. D. , After More Than a Decade of Foundational Leadership SOUTH…
globenewswire.com ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies…
zacks.com Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
seekingalpha.com ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
marketbeat.com ALX Oncology Q1 Earnings Call Highlights ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its…
benzinga.com ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses…
globenewswire.com ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable…- benzinga.com ALX Oncology Holdings Announces New Data Supporting Phase 1b/2 Clinical Trial For Evoracept In Combination With Jazz Pharmaceutical's Zanidatamab For Patients With Pre-Treated HER2-Positive Metastatic Breast Cancer The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior…
globenewswire.com ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -- benzinga.com ALX Oncology To Present New Data From Phase 1b/2 Clinical Trial Evaluating Investigational CD47-Inhibitor Evorpacept In Combination With Jazz's Zanidatamab In HER2-Positive mBC At ESMO Breast Cancer 2026 Congress - Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", ,…
globenewswire.com ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology";…
globenewswire.com ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel…
globenewswire.com ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
defenseworld.net ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 2,222,798 shares, a…
benzinga.com Wells Fargo Initiates Coverage On ALX Oncology Holdings with Overweight Rating, Announces Price Target of $5 Wells Fargo analyst Derek Archila initiates coverage on ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight rating and announces Price Target of $5.
benzinga.com HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $4 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintains $4 price target.
benzinga.com ALX Oncology Holdings Q4 Adj. EPS $(0.37) Misses $(0.36) Estimate ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.21 percent. This is a 15.91 percent increase over losses…
benzinga.com Earnings Scheduled For February 27, 2026 
benzinga.com A Look Ahead: ALX Oncology Holdings's Earnings Forecast - benzinga.com Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $4 Piper Sandler analyst Allison Bratzel maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight and raises the price target from $3 to $4.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com ALX Oncology Prices ~$150M Offering Of Common Share, Pre-Funded Warrants ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today…- benzinga.com ALX Oncology Data From Phase 1b/2 Clinical Study Of CD47-Inhibitor Evorpacept In Combination With Jazz Pharmaceuticals' ZIIHERA Demonstrates CD47 Expression Is Predictive Of Evorpacept Activity ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives,…
benzinga.com ALX Oncology Doses First Patient In Phase 2 ASPEN-09-Breast Trial Evaluating Its Investigational CD47-Inhibitor Evorpacept. - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com ALX Oncology Announced Earlier Sunday, Combination Of Evorpacept Plus Rituximab And Lenalidomide Generated Complete Responses In 92% Of Patients With Untreated Indolent Non-Hodgkin Lymphoma Comparing Favorably To ~50% Historical CR Rate For R2 Alone ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend…
- benzinga.com ALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 1.91 percent. This is a 20 percent increase over losses of…
benzinga.com Earnings Scheduled For November 7, 2025 - benzinga.com Examining the Future: ALX Oncology Holdings's Earnings Outlook
benzinga.com ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors-Robust body of preclinical…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For August 12, 2025